<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02128282</url>
  </required_header>
  <id_info>
    <org_study_id>S4-13-001</org_study_id>
    <nct_id>NCT02128282</nct_id>
  </id_info>
  <brief_title>Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma</brief_title>
  <official_title>A Phase I/II Study of CX-4945 in Combination With Gemcitabine and Cisplatin in the Frontline Treatment of Patients With Cholangiocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Senhwa Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Senhwa Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study considers the safety and tolerability of increasing doses of CX-4945 in&#xD;
      combination with gemcitabine plus cisplatin to determine the maximum tolerated dose (MTD) and&#xD;
      the recommended Phase II dose (RP2D), followed by a randomized study that compares antitumor&#xD;
      activity in cholangiocarcinoma patients receiving the standard of care gemcitabine plus&#xD;
      cisplatin versus CX-4945 at the combination RP2D with gemcitabine plus cisplatin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protein kinase CK2 is a constitutively active serine/threonine kinase with a long history as&#xD;
      a pro-survival, anti-apoptotic kinase. Given the wide spread overexpression of CK2 in&#xD;
      multiple cancers and its role in multiple non-oncogenic processes required to sustain the&#xD;
      cancer phenotype, a selective inhibitor of CK2 is an attractive targeted approach to treating&#xD;
      cancer.&#xD;
&#xD;
      CX-4945 is a tetracyclic, small molecule carboxylate acid salt that exhibits potent and&#xD;
      highly selective inhibition of CK2. Protein kinase CK2 is also known to play an important&#xD;
      role in the DNA damage repair mechanisms of cancer cells, and this study of CX-4945 in&#xD;
      combination with gemcitabine plus cisplatin will determine if inhibition of CK2, in&#xD;
      conjunction with the use of chemotherapy drugs, will result in improved clinical outcomes for&#xD;
      patients with non-resectable cholangiocarcinoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2014</start_date>
  <completion_date type="Actual">August 5, 2021</completion_date>
  <primary_completion_date type="Actual">November 6, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of CX-4945 when used in combination with gemcitabine plus cisplatin. (Phase 1)</measure>
    <time_frame>Cycle 1, 1 Full cycle up to twenty-one (21) days</time_frame>
    <description>The Maximum Tolerated Dose of CX-4945 will be determined from safety observations during the first cycle, as the CX-4945 dose is escalated in cohorts of three patients in combination with standard gemcitabine plus cisplatin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of the Progression-free survival (PFS) between the test and the control arms using Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 (Phase 2)</measure>
    <time_frame>From date of randomization to date of progression or death from any cause up to 52 weeks.</time_frame>
    <description>Tumor measurements will be compared to baseline every six weeks, and the PFS will be determined using RECIST v. 1.1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase II dose (RP2D) and schedule of CX-4945 in combination with gemcitabine plus cisplatin (Phase I)</measure>
    <time_frame>Cycle 1, 1 Full cycle up to twenty-one (21) days</time_frame>
    <description>The recommended Phase II dose and schedule of CX-4945 will be determined from safety observations during the first cycle, as the CX-4945 dose is administered 1000mg BID in 10-day continuous or 21-day continuous cohorts in combination with standard gemcitabine plus cisplatin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the Overall Response Rate (ORR) between the test and the control arms using Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1</measure>
    <time_frame>From date of randomization to date of progression or death from any cause up to 52 weeks.</time_frame>
    <description>Tumor measurements will be compared to baseline, and the ORR will be determined using RECIST v. 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the number of patient who transition to surgical resection</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months</time_frame>
    <description>The number of patients in the chemotherapy arm versus CX-4945 plus chemotherapy arm who transition to surgical resection will be compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the Overall Survival (OS) between the test and the control arms</measure>
    <time_frame>From date of randomization to date of death from any cause up to 52 weeks.</time_frame>
    <description>Time to event is observed during treatment and followed up every 3 months after patient withdraw from treatment.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">127</enrollment>
  <condition>Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>Escalation CX-4945 plus Cis/Gem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CX-4945 capsules at the combination MTD on Days 0, 1 and 2, and Days 7, 8 and 9.&#xD;
PLUS Cisplatin 25 mg/m.sq. by IV infusion on Days 1 and 8. PLUS Gemcitabine 1,000 mg/m.sq. by IV infusion on Days 1 and 8. On a 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cisplatin plus Gemcitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cisplatin 25 mg/m.sq. by IV infusion on Days 1 and 8. PLUS Gemcitabine 1,000 mg/m.sq. by IV infusion on Days 1 and 8. On a 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10-day CX-4945 plus Cis/Gem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CX-4945 capsules at 1000mg/BID, 10-day continuous dosing (Day 0 through Day 9). PLUS Cisplatin 25 mg/m.sq. by IV infusion on Days 1 and 8. PLUS Gemcitabine 1,000 mg/m.sq. by IV infusion on Days 1 and 8. On a 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>21-day CX-4945 plus Cis/Gem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CX-4945 capsules at 1000mg/BID, 21-day continuous dosing PLUS Cisplatin 25 mg/m.sq. by IV infusion on Days 1 and 8. PLUS Gemcitabine 1,000 mg/m.sq. by IV infusion on Days 1 and 8. On a 21-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CX-4945</intervention_name>
    <description>API powder-in-capsule in 200 mg strength.</description>
    <arm_group_label>10-day CX-4945 plus Cis/Gem</arm_group_label>
    <arm_group_label>21-day CX-4945 plus Cis/Gem</arm_group_label>
    <arm_group_label>Escalation CX-4945 plus Cis/Gem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>25 mg/m.sq. administered by IV infusion on Days 1 and 8 of a 21-day cycle.</description>
    <arm_group_label>10-day CX-4945 plus Cis/Gem</arm_group_label>
    <arm_group_label>21-day CX-4945 plus Cis/Gem</arm_group_label>
    <arm_group_label>Cisplatin plus Gemcitabine</arm_group_label>
    <arm_group_label>Escalation CX-4945 plus Cis/Gem</arm_group_label>
    <other_name>Platinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1,000 mg/m.sq. administered by IV infusion on Days 1 and 8 of a 21-day cycle.</description>
    <arm_group_label>10-day CX-4945 plus Cis/Gem</arm_group_label>
    <arm_group_label>21-day CX-4945 plus Cis/Gem</arm_group_label>
    <arm_group_label>Cisplatin plus Gemcitabine</arm_group_label>
    <arm_group_label>Escalation CX-4945 plus Cis/Gem</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presence of an unresectable hepatobiliary mass or metastatic disease (consistent with&#xD;
             cholangiocarcinoma, as evidenced by histology or cytology (augmented by fluorescence&#xD;
             in situ hybridization (FISH) where appropriate), for which treatment with gemcitabine&#xD;
             plus cisplatin is intended. Intrahepatic and extrahepatic cholangiocarcinoma patients&#xD;
             may be enrolled.&#xD;
&#xD;
          -  For patients enrolled in the Dose Escalation Phase, one or more tumors measurable on&#xD;
             radiograph or CT scan, or evaluable disease defined as non-measurable lesions per&#xD;
             RECIST v. 1.1 (e.g., malignant ascites). All patients enrolled to the Randomized Study&#xD;
             Phase must have measurable disease only.&#xD;
&#xD;
          -  Laboratory data as specified below:&#xD;
&#xD;
               -  Hematology: Absolute neutrophil count (ANC) &gt;1,500 cells/mm3, platelet count&#xD;
                  &gt;100,000 cells/ mm.cu. and hemoglobin &gt; 9 g/dL&#xD;
&#xD;
               -  Hepatic: bilirubin &lt;1.5 X Upper Limit of Normal (ULN); alkaline phosphatase&#xD;
                  (ALP), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &lt; 5.0 X&#xD;
                  ULN&#xD;
&#xD;
               -  Renal: serum creatinine within normal limits (WNL), defined as within 25% of the&#xD;
                  institution's stated reference range, or a calculated creatinine clearance &gt;45&#xD;
                  mL/min/1.73 m. sq. for patients with abnormal, increased, creatinine levels.&#xD;
&#xD;
               -  Coagulation: International Normalized Ratio (INR) &lt; 1.5 times normal, activated&#xD;
                  Partial Thromboplastin Time (aPTT) &lt; 1.5 times normal. Patients receiving&#xD;
                  therapeutic doses of anticoagulant therapy may be considered eligible for the&#xD;
                  trial if INR and aPTT are within the acceptable therapeutic limits for the&#xD;
                  institution.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0 - 1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A history of prior systemic treatment with gemcitabine or cisplatin. At least six&#xD;
             months must have elapsed if gemcitabine or cisplatin was administered in an adjuvant&#xD;
             treatment setting. Patients enrolled in the Expansion Cohort, Exploratory Cohorts, and&#xD;
             the Randomized Phase must not have received prior systemic chemotherapies, including&#xD;
             chemoradiation therapy for cholangiocarcinoma.&#xD;
&#xD;
          -  Seizure disorders requiring anticonvulsant therapy.&#xD;
&#xD;
          -  Known brain metastases (unless previously treated and well controlled for a period of&#xD;
             at least 3 months).&#xD;
&#xD;
          -  Major surgery other than diagnostic surgery, within 4 weeks prior to the first dose of&#xD;
             test drug, minor surgery including diagnostic surgery within 2 weeks (14 days)&#xD;
             excluding central IV port placements and needle aspirate/core biopsies. Radio&#xD;
             frequency ablation or transcatheter arterial chemoembolization within 6 weeks prior to&#xD;
             the first dose of test drug.&#xD;
&#xD;
          -  Treatment with radiation therapy or surgery within one month prior to study entry.&#xD;
&#xD;
          -  Treatment with chemotherapy or investigational drugs within 21 days prior to the&#xD;
             screening visit. Acute toxicities from prior therapy must have resolved to Grade ≤ 1&#xD;
             above baseline.&#xD;
&#xD;
          -  Patients with a history of another malignancy within 3 years of the baseline visit.&#xD;
             (Patients with cutaneous carcinomas or in-situ carcinomas will be considered for study&#xD;
             entry on a case-by-case basis).&#xD;
&#xD;
          -  Concurrent severe or uncontrolled medical disease (i.e., systemic infection, diabetes,&#xD;
             hypertension, coronary artery disease, congestive heart failure).&#xD;
&#xD;
          -  Active symptomatic fungal, bacterial and/or viral infection including active HIV or&#xD;
             viral (A, B or C) hepatitis which would not permit the patient to be managed according&#xD;
             to the protocol.&#xD;
&#xD;
          -  Difficulty with swallowing or an active malabsorption syndrome.&#xD;
&#xD;
          -  Chronic diarrhea (excess of 2-3 stools/day above normal frequency).&#xD;
&#xD;
          -  Gastrointestinal diseases including ulcerative colitis, Crohn's disease, or&#xD;
             hemorrhagic coloproctitis.&#xD;
&#xD;
          -  History of gastric or small bowel surgery involving any extent of gastric or small&#xD;
             bowel resection.&#xD;
&#xD;
          -  Clinically significant bleeding event within the last 3 months, unrelated to trauma,&#xD;
             or underlying condition that would be expected to result in a bleeding diathesis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitesh Borad, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259-5499</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado- Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang-Gung Memorial Hospital - Kaohsiung Branch</name>
      <address>
        <city>Kaohsiung City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospitals</name>
      <address>
        <city>Tainan City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang-Gung Memorial Hospital - Linkou Branch</name>
      <address>
        <city>Taoyuan City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 28, 2014</study_first_submitted>
  <study_first_submitted_qc>April 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2014</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cholangiocarcinoma</keyword>
  <keyword>Bile duct cancer</keyword>
  <keyword>Biliary tract cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

